EGFR and metastatic colorectal cancer: Thus, therapeutic agents, as tyrosine kinase inhibitors (erlotinib and gefinitib approved for the treatment of patients with non-small-cell lung cancer) or monoclonal antibodies (cetuximab for metastatic colorectal cancer, head and neck), which bind the tyrosine kinase and extracellular domain of EGFR, respectively, blocking its transactivation, might be considered as potential inhibitors of vp17-mediated B-cell clonogenicity in the setting of HIV lymphomagenesis.